NCT04864626
- Conditions
- Disease Attributes, Eating Disorders, Feeding and Eating Disorders, +7 more
- Locations
-
- CHU de SAINT-ETIENNE Saint-Etienne, France
Clinical trial condition
Recurrence
Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.
2,308 public trials
520 recruiting studies
Recurrence trial results
Active, Not Recruiting
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324
- Conditions
- Disease Attributes, Genital Diseases, Genital Diseases, Male, +12 more
- Locations
-
- Urology Centers of Alabama Homewood, Alabama, United States
- Ironwood Cancer & Research Centers Chandler, Arizona, United States
- Ironwood Cancer & Research Centers Gilbert, Arizona, United States
- Ironwood Cancer & Research Centers Glendale, Arizona, United States
Active, Not Recruiting
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
NCT06035497
- Conditions
- Disease Attributes, Hematologic Diseases, Hemic and Lymphatic Diseases, +26 more
- Locations
-
- Local Institution - 0031 Anjo-shi, Aichi-ken, Japan
- Local Institution - 0011 Nagoya, Aichi-ken, Japan
- Local Institution - 0024 Toyohashi, Aichi-ken, Japan
- Local Institution - 0017 Kamogawa, Chiba, Japan
Active, Not Recruiting
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
NCT01068249
- Conditions
- Disease Attributes, Endometrial Cancer, Endometrial Neoplasms, +14 more
- Locations
-
- Morristown Memorial Hospital, Women's Cancer Center Morristown, New Jersey, United States
- University of Texas MD Anderson Cancer Center Houston, Texas, United States
Active, Not Recruiting
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
NCT05359445
- Conditions
- Cancer, Disease Attributes, Neoplasms, +6 more
- Locations
-
- Universitaetsklinikum Freiburg, Zentralklinikum, Klinik fuer Innere Medizin I Freiburg im Breisgau, Baden-Wurttemberg, Germany
- Universitaetsklinikum Heidelberg AöR, Nationales Zentrum fuer Tumorkrankheiten Heidelberg, Baden-Wurttemberg, Germany
- Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie Heidelberg, Baden-Wurttemberg, Germany
- Universitaetsklinikum Tuebingen AöR, Comprehensive Cancer Center Tuebingen Tübingen, Baden-Wurttemberg, Germany
Active, Not Recruiting
Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
NCT04551131
- Conditions
- Disease Attributes, Hemic and Lymphatic Diseases, Hemophagocytic Lymphohistiocytosis, +7 more
- Locations
-
- Phoenix Children's Hospital Phoenix, Arizona, United States
- Children's Hospital of Orange County Orange, California, United States
- University of California San Francisco San Francisco, California, United States
- Children's National Medical Center Washington D.C., District of Columbia, United States
Active, Not Recruiting
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
NCT05253118
- Conditions
- DLBCL, Disease Attributes, Pathologic Processes, +2 more
- Locations
-
- Seoul National University Hospital Seoul, South Korea
Active, Not Recruiting
ctDNA for Early Detection of Recurrence in Melanoma
NCT06246227
- Conditions
- Disease Attributes, Melanoma, Neoplasms, +13 more
- Locations
-
- Detp. of Pastic and Reconstructive Surgery, Herlev Hospital Herlev, Denmark
Active, Not Recruiting
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493
- Conditions
- Disease Attributes, Follicular Lymphoma (FL), Hemic and Lymphatic Diseases, +12 more
- Locations
-
- Novartis Investigative Site Camperdown, New South Wales, Australia
- Novartis Investigative Site Clayton, Victoria, Australia
- Novartis Investigative Site Melbourne, Victoria, Australia
- Novartis Investigative Site Nedlands, Western Australia, Australia
Active, Not Recruiting
AB154 Combined With AB122 for Recurrent Glioblastoma
NCT04656535
- Conditions
- Astrocytoma, Disease Attributes, Glioblastoma, +11 more
- Locations
-
- University of California San Francisco San Francisco, California, United States
- Yale University New Haven, Connecticut, United States
- Dana Farber Cancer Institute Boston, Massachusetts, United States